Metabolites of soil microorganisms modulate amyloid β production in Alzheimer’s neurons

1. Fleming, A. On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenz?

Br. J. Exp. Pathol. 10, 226 (1929).

2. Newman, D. J. & Cragg, G. M. Natural products as sources of new drugs from 1981 to 2014. J. Nat. Prod. 79, 629–661 (2016).

3. Liu, R., Li, X. & Lam, K. S. Combinatorial chemistry in drug discovery. Curr. Opin. Chem. Biol. 38, 117–126 (2017).

4. Li, J. W. H. & Vederas, J. C. Drug discovery and natural products: End of an era or an endless frontier? Science 325, 161–165 (2009).

5. Shen, B. A new golden age of natural products drug discovery. Cell 163, 1297–1300 (2015).

6. Deshmukh, S. K., Gupta, M. K., Prakash, V. & Saxena, S. Endophytic fungi: A source of potential antifungal compounds. J. Fungi

4, 77 (2018).

7. Kurm, V., van der Putten, W. H. & Hol, W. H. G. Cultivation-success of rare soil bacteria is not influenced by incubation time and

growth medium. PLoS ONE 14, e0210073 (2019).

8. Chaudhary, D. K., Khulan, A. & Kim, J. Development of a novel cultivation technique for uncultured soil bacteria. Sci. Rep. 9, 1–11

(2019).

9. Arisawa, A. & Watanabe, A. Pursuing the unlimited potential of microorganisms—Progress and prospect of a fermentation company. Biosci. Biotechnol. Biochem. 81, 43–47 (2017).

10. Hover, B. M. et al. Culture-independent discovery of the malacidins as calcium-dependent antibiotics with activity against multidrug-resistant Gram-positive pathogens. Nat. Microbiol. 3, 415–422 (2018).

11. Sureda, A. et al. Oral microbiota and Alzheimer’s disease: Do all roads lead to Rome? Pharmacol. Res. 151, 104582 (2020).

12. Pascale, A., Marchesi, N., Govoni, S. & Barbieri, A. Targeting the microbiota in pharmacology of psychiatric disorders. Pharmacol.

Res. 157, 104856 (2020).

13. Lin, C. et al. Microbiota-gut-brain axis and toll-like receptors in Alzheimer’s disease. Comput. Struct. Biotechnol. J. 17, 1309–1317

(2019).

14. Fujii, Y., Khasnobish, A. & Morita, H. Relationship between Alzheimer’s disease and the human microbiome. In Alzheimer’s Disease

(ed. Wisniewski, T.) 147–158 (Codon Publications, 2019).

15. Kumar, D. K. V. et al. Amyloid-β peptide protects against microbial infection in mouse and worm models of Alzheimer’s disease.

Sci. Transl. Med. https://​doi.​org/​10.​1126/​scitr​anslm​ed.​aaf10​59 (2016).

16. Eimer, W. A. et al. Alzheimer’s disease-associated β-amyloid is rapidly seeded by herpesviridae to protect against brain infection.

Neuron 99, 56–63 (2018).

17. Bocharova, O., Molesworth, K., Pandit, N. P. & Baskakov, I. V. Alzheimer’s disease-associated β-amyloid does not protect against

herpes simplex virus 1 brain infection. BioRxiv. https://​doi.​org/​10.​1101/​2021.​01.​21.​427570 (2021).

18. Michiels, E., Rousseau, F. & Schymkowitz, J. Mechanisms and therapeutic potential of interactions between human amyloids and

viruses. Cell. Mol. Life Sci. 78, 2485–2501 (2021).

19. Yu, H. & Wu, J. Amyloid-β: A double agent in Alzheimer’s disease? Biomed. Pharmacother. 139, 111575 (2021).

20. Kondo, T. et al. Modeling Alzheimer’s disease with iPSCs reveals stress phenotypes associated with intracellular Aβ and differential

drug responsiveness. Cell Stem Cell 12, 487–496 (2013).

21. Kondo, T. et al. iPSC-based compound screening and in vitro trials identify a synergistic anti-amyloid β combination for Alzheimer’s disease. Cell Rep. 21, 2304–2312 (2017).

22. Crouch, S. P. M., Kozlowski, R., Slater, K. J. & Fletcher, J. The use of ATP bioluminescence as a measure of cell proliferation and

cytotoxicity. J. Immunol. Methods 160, 81–88 (1993).

23. Jacobs, A. C. et al. Adenylate kinase release as a high-throughput-screening-compatible reporter of bacterial lysis for identification

of antibacterial agents. Antimicrob. Agents Chemother. 57, 26–36 (2013).

24. Miret, S., De Groene, E. M. & Klaffke, W. Comparison of in vitro assays of cellular toxicity in the human hepatic cell line HepG2.

J. Biomol. Screen. 11, 184–193 (2006).

25. Astashkina, A., Mann, B. & Grainger, D. W. A critical evaluation of in vitro cell culture models for high-throughput drug screening

and toxicity. Pharmacol. Ther. 134, 82–106 (2012).

Scientific Reports |

(2022) 12:2690 |

https://doi.org/10.1038/s41598-022-06513-z

Vol.:(0123456789)

www.nature.com/scientificreports/

A Self-archived copy in

Kyoto University Research Information Repository

https://repository.kulib.kyoto-u.ac.jp

26. Palanivel, K., Kanimozhi, V., Kadalmani, B. & Akbarsha, M. A. Verrucarin A, a protein synthesis inhibitor, induces growth inhibition and apoptosis in breast cancer cell lines MDA-MB-231 and T47D. Biotechnol. Lett. 35, 1395–1403 (2013).

27. Morrell, C. M. & Adams, J. A. Toxicity of Verrucarin A to gametes and embryos of the purple sea urchin (Arbacia punctulata).

Bull. Environ. Contam. Toxicol. 51, 889–894 (1993).

28. Kominato, K. et al. Mer-A2026A and B, Novel piericidins with vasodilating effect: II. Physico-chemical properties and chemical

structures. J. Antibiot. (Tokyo) 48, 103–105 (1995).

29. Jonsson, T. et al. A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline. Nature 488, 96–99

(2012).

30. Emery, D. C. et al. 16S rRNA next generation sequencing analysis shows bacteria in Alzheimer’s post-mortem brain. Front. Aging

Neurosci. https://​doi.​org/​10.​3389/​fnagi.​2017.​00195 (2017).

31. Choi, J. et al. Strategies to improve reference databases for soil microbiomes. ISME J. 11, 829–834 (2017).

32. Smith, G. R., Crowther, T. W., Eisenhauer, N. & van den Hoogen, J. Building a global database of soil microbial biomass and function: A call for collaboration. Soil Org. 91, 139–142 (2020).

33. Kawahara, T., Nagai, A., Takagi, M. & Shin-ya, K. JBIR-137 and JBIR-138, new secondary metabolites from Aspergillus sp. fA75.

J. Antibiot. (Tokyo) 65, 535–538 (2012).

34. Kawahara, T. et al. Three eremophilane derivatives, MBJ-0011, MBJ-0012 and MBJ-0013, from an endophytic fungus Apiognomonia sp. f24023. J. Antibiot. (Tokyo) 66, 299–302 (2013).

35. Kawahara, T. et al. New hydroxamate metabolite, MBJ-0003, from Micromonospora sp. 29867. J. Antibiot. (Tokyo) 67, 261–263

(2014).

36. Kawahara, T. et al. Novel aziridine-containing peptides MBJ-0034 and MBJ-0035 from Streptosporangium sp. 32552. J. Antibiot.

(Tokyo) 67, 577–580 (2014).

37. Kawahara, T. et al. MBJ-0086 and MBJ-0087, new bicyclic depsipeptides, from Sphaerisporangium sp. 33226. J. Antibiot. (Tokyo)

68, 67–70 (2015).

38. Kawahara, T. et al. MBJ-0110, a novel cyclopeptide isolated from the fungus Penicillium sp. f25267. J. Antibiot. (Tokyo) 69, 66–68

(2016).

Acknowledgements

We would like to express our sincere gratitude to all our coworkers and collaborators; to Ayako Nagahashi for

technical assistance, and to Kimie Iijima, Nozomi Kawabata, Makiko Yasui, Tomomi Urai and Miho Nagata for

their valuable administrative support. This research was funded in part by the grant for Core Center for iPSC

Research of Research Center Network for Realization of Regenerative Medicine from AMED (H.I.); and JSPS

KAKENHI Grant-in-Aid for Young Scientists 17K16121, 20K16599 (T.K.). The experimental protocols dealing with human subjects were approved by the institutional review board of Graduate School and Faculty of

Medicine Kyoto University.

Author contributions

H.I. conceived the project. T.K. and H.I. designed the experiment. T.K. and H.I. performed the experiments and

analyzed the data. T.Y., K.O. and H.N. provided compound libraries and critical comments on microorganisms.

Competing interests Kyoto University has a patent related to the secondary metabolites of soil microbiota in this manuscript: Patent No. WO2019/198825, titled “Prophylactic, therapeutic, or diagnostic drug for Alzheimer’s disease using

microorganism-derived compound” with inventors H.I. and T.K. Tsuyoshi Yamamoto, Kaoru Okayama, and

Hideki Narumi are employees of MicroBiopharma Japan Co., Ltd.

Additional information

Supplementary Information The online version contains supplementary material available at https://​doi.​org/​

10.​1038/​s41598-​022-​06513-z.

Correspondence and requests for materials should be addressed to H.I.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and

institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International

License, which permits use, sharing, adaptation, distribution and reproduction in any medium or

format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the

Creative Commons licence, and indicate if changes were made. The images or other third party material in this

article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the

material. If material is not included in the article’s Creative Commons licence and your intended use is not

permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from

the copyright holder. To view a copy of this licence, visit http://​creat​iveco​mmons.​org/​licen​ses/​by/4.​0/.

© The Author(s) 2022

Scientific Reports |

Vol:.(1234567890)

(2022) 12:2690 |

https://doi.org/10.1038/s41598-022-06513-z

10

...